Clarity Pharmaceuticals Ltd. (AU:CU6)
ASX:CU6
Want to see AU:CU6 full AI Analyst Report?
Top Page
Clarity Pharmaceuticals Ltd.
(Sydney:CU6)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$3.00
▼(-4.15% Downside)
Action:ReiteratedDate:04/16/26
The score is driven primarily by weak financial performance: widening losses, negative free cash flow, and a shrinking equity base, partially mitigated by a debt-free balance sheet. Technicals also weigh on the score, with the stock trading below key moving averages and negative MACD. Valuation provides limited support due to losses (negative P/E) and no dividend yield data.
Positive Factors
Debt-free balance sheet
Zero reported debt materially reduces financial risk and eliminates interest burden, giving management structural flexibility to fund R&D and clinical programs via equity or partnerships. For a cash-burning biotech, a debt-free position lowers default risk and preserves optionality over months.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow creates a structural funding requirement: the company must repeatedly access equity or partners to sustain clinical programs. Over 2–6 months this raises dilution risk, forces program prioritization, and limits ability to self-fund multiple development pathways.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt materially reduces financial risk and eliminates interest burden, giving management structural flexibility to fund R&D and clinical programs via equity or partnerships. For a cash-burning biotech, a debt-free position lowers default risk and preserves optionality over months.
Read all positive factors
Clarity Pharmaceuticals Ltd. (CU6) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.10B
Dividend YieldN/A
Average Volume (3M)3.27M
Price to Earnings (P/E)―
Beta (1Y)2.46
Revenue GrowthN/A
EPS Growth-29.93%
CountryAU
Employees50
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.15
Shares Outstanding372,258,100
10 Day Avg. Volume4,406,737
30 Day Avg. Volume3,266,690
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)8.84
Price to Sales (P/S)84.33
P/FCF Ratio-14.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$7.46Price Target Upside138.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.3
Revenue Forecast (FY)AU$4.33M
Clarity Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmac...
How the Company Makes Money
null...
Clarity Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.77M | 9.46M | 11.51M | 9.80M | 6.46M | 3.20M |
| Gross Profit | 4.62M | 9.46M | 11.51M | 9.70M | 6.41M | 3.18M |
| EBITDA | -101.51M | -68.91M | -44.65M | -34.20M | -30.15M | -13.38M |
| Net Income | -96.25M | -64.30M | -42.32M | -24.60M | -23.75M | -10.22M |
Balance Sheet | ||||||
| Total Assets | 255.67M | 101.17M | 154.63M | 76.90M | 99.82M | 22.61M |
| Cash, Cash Equivalents and Short-Term Investments | 226.25M | 84.12M | 136.51M | 65.01M | 92.34M | 18.94M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 22.86M | 10.94M | 8.33M | 7.72M | 7.59M | 2.34M |
| Stockholders Equity | 232.81M | 90.23M | 146.30M | 69.18M | 92.24M | 20.28M |
Cash Flow | ||||||
| Free Cash Flow | -72.59M | -54.95M | -43.74M | -27.55M | -13.53M | -7.74M |
| Operating Cash Flow | -72.26M | -54.77M | -43.24M | -27.50M | -13.31M | -7.68M |
| Investing Cash Flow | -47.91M | 51.99M | -55.31M | 3.15M | -26.71M | -60.31K |
| Financing Cash Flow | 193.45M | 2.21M | 115.21M | 231.58K | 86.93M | 10.91M |
Clarity Pharmaceuticals Ltd. Technical Analysis
Negative
3.13
Price Trends
3.33
Negative
3.35
Negative
3.66
Negative
Market Momentum
-0.08
Positive
47.10
Neutral
59.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CU6, the sentiment is Negative. The current price of 3.13 is below the 20-day moving average (MA) of 3.19, below the 50-day MA of 3.33, and below the 200-day MA of 3.66, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 47.10 is Neutral, neither overbought nor oversold. The STOCH value of 59.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CU6.
Clarity Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$444.27M | 14.96 | 13.29% | 0.38% | 7.76% | 1.55% | |
60 Neutral | AU$4.89B | -342.48 | -2.08% | ― | 60.23% | -66.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.27B | -10.86 | -30.03% | ― | ― | -5.70% | |
48 Neutral | AU$87.05M | -2.00 | -131.13% | ― | 456.50% | -457.14% | |
44 Neutral | AU$1.10B | -5.54 | -59.59% | ― | ― | -29.93% | |
42 Neutral | AU$109.06M | -3.40 | -69.20% | ― | ― | -19.21% |
* Healthcare Sector Average
AU:CU6
Clarity Pharmaceuticals Ltd.
2.94
0.84
40.00%
AU:CUV
Clinuvel Pharmaceuticals
9.04
-1.72
-15.97%
AU:IMM
Immutep Ltd
0.07
-0.18
-72.00%
AU:TLX
Telix Pharmaceuticals
14.90
-11.78
-44.15%
AU:PYC
PYC Therapeutics Limited
1.30
0.21
19.03%
AU:BOT
Botanix Pharmaceuticals Limited
0.03
-0.39
-92.14%
Clarity Pharmaceuticals Ltd. Corporate Events
Clarity Expands U.S. Manufacturing Network for Prostate Cancer Imaging Agent
Apr 13, 2026
Clarity Pharmaceuticals has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for Cu-64 SAR-bisPSMA, expanding its U.S. manufacturing footprint through facilities in Rochester, Minnesota, and a planned large-scale site in Spring...
Citigroup Ceases to Be Substantial Holder in Clarity Pharmaceuticals
Apr 10, 2026
Citigroup Global Markets Australia Pty Limited and related Citi group entities have notified Clarity Pharmaceuticals that they have ceased to be a substantial shareholder as of 8 April 2026, ending their previous substantial holding status in the ...
Clarity Pharmaceuticals Director Colin Biggin Steps Down but Retains Significant Equity Stake
Apr 9, 2026
Clarity Pharmaceuticals has announced that director Colin David Biggin has ceased to be a director of the company as of 8 April 2026. A final director’s interest notice filed with the ASX details that Biggin retains holdings in the company, ...
Clarity Pharmaceuticals Reshapes Board as It Moves Toward Commercial Launch
Apr 8, 2026
Clarity Pharmaceuticals has announced a change to its board, with Executive Director Dr Colin Biggin stepping down from the board while continuing in his operational role as Chief Operating Officer. The move is part of a broader corporate governan...
Clarity Pharmaceuticals Issues New Unquoted Options Under Employee Incentive Scheme
Apr 7, 2026
Clarity Pharmaceuticals has notified the market of the issue of 59,857 unquoted options under an employee incentive scheme, recorded as two tranches of CU6AAM options with varying expiry dates and exercise prices. The new options, issued on 23 and...
Clarity Pharmaceuticals Issues New Shares on Option Exercise in Routine Capital Move
Mar 31, 2026
Clarity Pharmaceuticals has issued 1,117 fully paid ordinary shares following the exercise of options, expanding its share capital on the ASX. The company confirmed the shares were issued without a prospectus under the Corporations Act, while stat...
Clarity Pharmaceuticals Seeks ASX Quotation for Small Tranche of New Shares
Mar 31, 2026
Clarity Pharmaceuticals Ltd., listed on the ASX under ticker CU6, has applied for quotation of a small tranche of 1,117 new ordinary fully paid shares. The securities, issued on 31 March 2026, arise from the exercise or conversion of existing opti...
Clarity’s PSMA Imaging Agent Shows Superior Performance in Key Prostate Cancer Study
Mar 31, 2026
Clarity Pharmaceuticals has reported that results from the investigator-initiated Co-PSMA phase II trial of its copper-64 based PSMA imaging agent, 64Cu-SAR-bisPSMA, have been published in the high-impact journal European Urology, reinforcing earl...
Clarity Secures Major U.S. Copper-64 Supply Deal with Theragenics
Mar 24, 2026
Clarity Pharmaceuticals has signed a large-scale manufacturing supply agreement with Theragenics for copper-64 production at Theragenics’ high-capacity cyclotron facility near Atlanta, Georgia, positioning the company for commercial rollout ...
Clarity’s 64Cu-SAR-bisPSMA tops standard imaging in prostate cancer trial
Mar 16, 2026
Clarity Pharmaceuticals reported that data from its Phase II Co-PSMA investigator-initiated trial of 64Cu-SAR-bisPSMA in men with biochemical recurrence of prostate cancer were presented at the European Association of Urology Congress 2026 and acc...
Clarity Pharmaceuticals Issues New Shares via Option Exercises, Confirms Regulatory Compliance
Mar 11, 2026
Clarity Pharmaceuticals has issued 226,885 fully paid ordinary shares following the exercise of options, expanding its issued capital base without providing a disclosure document to investors under the Corporations Act. The company confirmed it is...
Clarity Pharmaceuticals Seeks ASX Quotation for New Share Issuance
Mar 11, 2026
Clarity Pharmaceuticals has applied to the ASX for quotation of 226,885 new ordinary fully paid shares under its CU6 ticker, with the securities issued on 10 March 2026. The additional shares arise from the exercise or conversion of existing optio...
Clarity hits Phase III AMPLIFY enrollment goal for prostate cancer imaging agent
Mar 9, 2026
Clarity Pharmaceuticals has reached the target number of participants in its registrational Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA PET imaging for men with biochemical recurrence of prostate cancer after definitive treatment in the U.S. and A...
Clarity Pharmaceuticals Issues Additional Unquoted Employee Options
Mar 2, 2026
Clarity Pharmaceuticals has notified the market of the issue of unquoted options under its employee incentive scheme, covering a total of 119,968 options in two tranches dated 12 January and 26 January 2026. The move underscores the company’...
Clarity Pharmaceuticals Releases 2026 Interim Report Detailing Pipeline and Financial Progress
Feb 27, 2026
Clarity Pharmaceuticals has released its 2026 interim report and half-year financial statements for the period ended 31 December 2025, outlining key operational and corporate highlights. The report details progress in clinical and regulatory devel...
Clarity Pharmaceuticals Posts Wider Half-Year Loss but Lifts Net Tangible Assets
Feb 27, 2026
Clarity Pharmaceuticals reported no revenue from ordinary activities for the half-year to 31 December 2025, while its net loss attributable to owners widened sharply to about A$55.6 million. The company did not pay or declare any dividends for the...
Clarity flags more prostate cancer patients with no detectable disease in SECuRE trial
Feb 22, 2026
Clarity Pharmaceuticals reported that another participant in the Phase II Cohort Expansion of its SECuRE trial for metastatic castration-resistant prostate cancer achieved undetectable prostate-specific antigen after the first cycle and a negative...
Clarity Advances Late-Stage Radiopharmaceutical Pipeline on Strong Cash Base
Jan 30, 2026
Clarity Pharmaceuticals reported a strong cash position of $226.2 million as of 31 December 2025, underpinning its ability to advance multiple late-stage clinical programs. In its SECuRE Phase II trial of 67Cu-SAR-bisPSMA for prostate cancer, an i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.